Safety
leukoSTAT™ ( ImSAIDs® Enabled)
The ImSAIDs® are comprised of natural amino acids that have demonstrated no toxicity or immune suppression in numerous animal studies, including dogs, cats, and a variety of other species
leukoSTAT™ contains the ImSAIDs®; patented amino acid complexes that maintain systemic health, by aiding in the reduction of leukocyte activation and chemotaxis. ImSAIDs® are Not COX/LOX inhibitors or steroids, but naturally occuring amino acid complexes that nature designed to positively influence the immune system, including leukocytes.
ImSAIDs® - Cellular Modulation in vivo and in vitro results have shown the ImSAIDs® to help support the following: reduce granulocyte activation and chemotaxis diminish oxidative burst capacity and the production of reactive oxygen species attenuate the effects of endotoxin, and reduce allergic & anaphylactic reactions (type I hypersensitivity and IgE-mediated reactions)
Additional References on ImSAIDs® Immunopharmacology Mathison R, et al. Modulation of neutrophil function by the tripeptide feG. BMC Immunol. 2003 Mar 4;4:3. 2003 Mathison R, et al. Regulation of leukocyte adhesion to heart by the tripeptides feG and feG(NH2). Can J Physiol Pharmacol. 2001 Sep; 79(9):785-92. Mathison RD and Davison JS. The Tripeptide feG Regulates the Production of Intracellular Reactive Oxygen Species by Neutrophils. J Inflamm (Lond). 2006 Jun 15;3(1):9 Mathison R, Davison JS, Befus AD. Neuroendocrine regulation of inflammation and tissue repair by submandibular gland factors. Immunol Today.1994 Nov;15(11):527-32. Mathison RD, et al. The tripeptide feG inhibits leukocyte adhesion. J Inflamm (Lond). 2008 May 20;5:6. Mathison R, Davison JS. Molecular characteristics of the tripeptide feG accounting for different biological activities. Proc West Pharmacol Soc. 2007;50:101-4. Mathison RD, et al.. A peptide from the submandibular glands modulates inflammatory responses. Int Arch Allergy Immunol. 1997 May-Jul;113(1-3):337-8. Mathison RD, et al. Submandibular glands: novel structures participating in thermoregulatory responses. Can J Physiol Pharmacol. 1997 May; 75(5):407-13.
leukoSTAT™ Product & Ordering IMULAN has developed a highly palatable, chewable tablet for dogs and cats. The small, 625mg chewable tablet can be used when only small amounts of material can be given orally. leukoSTAT™ is available in 30 and 120 count bottles. To purchase LeukoSTAT™; please go to www.IMULAN.com and set up an account. You may also contact IMULAN at info@ imulan.com
IMULAN BioTherapeutics 4221 Mitchell Avenue St. Joseph, MO 64507 www.IMULAN.com 480-248-2176
.
Immuno-Nutritional Technology ALL Inflammation is Regulated by Leukocytes
Acute pancreatitis 8
Lipase Units x 103/mL
The ImSAIDs® (Immune Selective AntiInflammatory Derivatives) are a brand new amino acid technology designed by Mother Nature. The ImSAIDs® are naturally occuring amino acid complexes that nature designed to help reduce over activation of the immune response.
Anaphylaxis
7 6 5 4
*
*
3 2 1 0
Critical Care Medicine Models
Normal, no pancreatitis
The ImSAIDs have been evaluated in a variety of comparative disease models of sepsis, endotoxemia, spinal trauma, pancreatitis, asthma, allergic and anaphylactic reactions. The following are models using one ImSAID® amino acid complex, phe-glu-gly, or feG.
No treatment
ImSAIDs (0hr)
ImSAIDs (3hr)
Neutrophil count, mean ± sem, n=5
ImSAIDs® Key Benefits
35 30
25
Neutrophil inhibition after after intestinal anaphylaxis Sensitized control ImSAID treated Dexamethasone
20 15 10 5 0 0.5
3
Hours after challenge
24
Pancreatitis Model
Allergic/Anaphylaxis/IgE mediated Model
Rifai Y, et al. The tripeptide analog feG ameliorates severity of acute pancreatitis in a caerulein mouse model. Am J Physiol Gastrointest Liver Physiol.2008 Apr;294(4):G1094-9.
Turesin F, et al.: The tripeptide FEG ameliorates systemic inflammatory responses to rat intestinal anaphylaxis. BMC Physiol 2002, 2:13
CONTROL; severe cellular infiltration (lung)
units MPO/mg tissue, mean ± sem, n=6
Chemotaxis, adhesion Inhibition of neutrophil chemotaxis
0.3
0.25
ImSAIDs (1mg/kg); mild cellular infiltration
0.2
0.15
0.1
0.05
0
0.35
1
3.5
10
100
ImSAID dosage, µg/kg
Neurological Trauma Model Endotoxin/Sepsis Model Tan D, et al. The carboxamide feG(NH2) inhibits endotoxin perturbation of intestinal motility. Eur J Pharmacol. 2000 Dec 8;409(2):203-5. Mathison R, et al. The tripeptide feG reduces endotoxin-provoked perturbation of intestinal motility and inflammation. Neurogastroentero Motil. 2001 Dec;13(6):599-603.
Bao F, et al. The tripeptide phenylalanine-(D) glutamate-(D) glycine modulates leukocyte infiltration and oxidative damage in rat injured spinal cord. Neuroscience. 2006 Jul 7;140(3):1011-22. John SM, Bao F, Chen Y, Mathison RD, Weaver LC.Effects of a novel tripeptide on neurological outcomes after spinal cord injury. Neuroreport. 2006 Nov 27;17(17):1793-6.
Inflammation/Asthma Model Dery RE, et al. Frontline: Inhibition of allergen-induced pulmonary inflammation by the tripeptide feG: a mimetic of a neuro-endocrine pathway. Eur J Immunol. 2004 Dec;34(12):3315-25.